TY - JOUR
T1 - Brain/MINDS
T2 - A Japanese National Brain Project for Marmoset Neuroscience
AU - Okano, Hideyuki
AU - Sasaki, Erika
AU - Yamamori, Tetsuo
AU - Iriki, Atsushi
AU - Shimogori, Tomomi
AU - Yamaguchi, Yoko
AU - Kasai, Kiyoto
AU - Miyawaki, Atsushi
N1 - Funding Information:
We appreciate Charles Yokoyama for critical reading and invaluable comments on the manuscript, Drs. Shigeo Okabe and Yutaka Hishiyama for their continuous encouragement, Akiya Watakabe, Fumiko Seki, Shinsuke Shibata, and Jun-ichi Hata for preparing the manuscript, and all members of Brain/MINDS for their enormous contributions. This work is supported by Brain/MINDS and the Strategic Research Program for Brain Sciences from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) and Japan Agency for Medical Research and Development (AMED). A.I. is the President and CEO and Y.Y. is a director of RIKÆNALYSIS Corporation (RIKEN Venture Company). H.O. is a paid Scientific Advisory Board of SanBio Co Ltd. The other authors declare no competing financial interests.
Funding Information:
In 2013, following a remarkable convergence of scientific advocacy and political vision, two large-scale national research projects, the U.S. BRAIN Initiative and the EU Human Brain Project (HBP), were launched to accelerate the scientific understanding of the brain. In Japan, this movement mobilized the neuroscience community to consider how to contribute to global affairs in neuroscience. Policy discussions identified brain research in non-human primates as a necessary step to bridge fundamental advances from current animal models, such as the mouse, to an accurate understanding of the human brain. For disease studies, in particular, scientific knowledge from the primate brain was seen as an indispensable component of translational research toward evidence-based diagnosis and treatment of human psychiatric, neurological, and neurodegenerative disorders. The conclusion of this discussion called for Japan to adopt a fundamentally different approach compared to the larger scale and broader scope of the U.S. and EU brain projects, by focusing on accelerating the development of the common marmoset (Callithrix jacchus), a small new world primate, as a model for exploration and discovery of knowledge-based strategies for the eradication of major brain disorders ( Grillner et al., 2016; Okano et al., 2015; Okano and Yamamori, 2016 ). Based on these considerations, the Brain/MINDS (Brain Mapping by Integrated Neurotechnologies for Disease Studies) initiative was launched in June 2014 with support from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) and the newly formed Japan Agency for Medical Research and Development (AMED) (see Box 1 in detail). The 10 year roadmap for Brain/MINDS mandates completion of a multiscale marmoset brain atlas and integrated data platform to support functional studies, the generation of genetically modified (GM) marmosets for experimental and pre-clinical studies, and the creation of a clinical data center using translational biomarkers for the diagnosis and treatment of human brain diseases ( Figure 1 ).
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/11/2
Y1 - 2016/11/2
N2 - Brain/MINDS (Brain Mapping by Integrated Neurotechnologies for Disease Studies) is a national brain project started by Japan in 2014. With the goal of developing the common marmoset as a model animal for neuroscience, the project aims to build a multiscale marmoset brain map, develop new technologies for experimentalists, create transgenic lines for brain disease modeling, and integrate translational findings from the clinical biomarker landscape. Brain/MINDS will collaborate with global brain projects to share technologies and resources.
AB - Brain/MINDS (Brain Mapping by Integrated Neurotechnologies for Disease Studies) is a national brain project started by Japan in 2014. With the goal of developing the common marmoset as a model animal for neuroscience, the project aims to build a multiscale marmoset brain map, develop new technologies for experimentalists, create transgenic lines for brain disease modeling, and integrate translational findings from the clinical biomarker landscape. Brain/MINDS will collaborate with global brain projects to share technologies and resources.
UR - http://www.scopus.com/inward/record.url?scp=84994716174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994716174&partnerID=8YFLogxK
U2 - 10.1016/j.neuron.2016.10.018
DO - 10.1016/j.neuron.2016.10.018
M3 - Short survey
C2 - 27809998
AN - SCOPUS:84994716174
SN - 0896-6273
VL - 92
SP - 582
EP - 590
JO - Neuron
JF - Neuron
IS - 3
ER -